PBRM1 biomarkers predictive of anti-immune checkpoint response

A method of treating a cancer in a subject likely to be responsive to an immune checkpoint therapy, wherein the immune checkpoint therapy comprises nivolumab, the method comprising

• i) selecting the subject, the subject having been identified according to:
• a) obtaining or providing a subject sample from a patient having cancer;
• b) measuring the amount or activity of PBRM1 in the subject sample;
• and
• c) comparing the amount or activity of PBRM1 in a control sample,
• wherein the absence of or a significantly decreased amount or activity of PBRM1 in the subject sample and/or the presence of or a significantly increased amount or activity of PBRM1 having a loss of function mutation in the subject sample, relative to the control sample identified the cancer as being likely to be responsive to the immune checkpoint therapy;
• and
• ii) administering the immune checkpoint therapy to the selected subject.